A magnesium deficiency, with symptoms ranging from fatigue and muscle weakness to severe seizures and heart rhythm disturbances, is also associated with diabetes and high blood pressure. Up until now it has been mostly explained by dietary insufficiencies. The research team has now shown that an altered gene may be the cause for this deficiency.
Changes in a gene (Cnnm2), entail changes in the human blueprint and thus in the structure and function of protein sequence. In this case, the change affects a protein that is anchored in the membrane of kidney cells and intestinal cells and is responsible for the absorption of magnesium in the blood stream. Since this process no longer works in the defective protein, the magnesium is not put into the blood stream but excreted through the intestine and the urine, and therefore forfeited. The results provide scientists with a number of new insights into magnesium metabolism in the body. Further research and development will create more possibilities in how to most easily deal with this genetic deficiency.
Given this discovery, here is what one can do in the interim:
- To ensure that you most easily absorb your magnesium, you must supplement with a glycinate form. Lesser forms such as oxide or aspartate will not be sufficient. The amino acid glycine will at least ensure that the magnesium molecule is pulled through the intestinal receptor without interference and will be somewhat processed in the bloodstream. Working with a licensed expert in vitamin/mineral supplementation is imperative to find a dose that will bring your magnesium levels beyond a suboptimal level.
- If option number one does not suffice, intravenous magnesium sulfate under the supervision of your physician may be necessary.
Familial hypomagnesemia is a rare human disorder caused by renal or intestinal magnesium (Mg2+) wasting, which may lead to symptoms of Mg2+ depletion such as tetany, seizures, and cardiac arrhythmias. Our knowledge of the physiology of Mg2+ (re)absorption, particularly the luminal uptake of Mg2+ along the nephron, has benefitted from positional cloning approaches in families with Mg2+ reabsorption disorders; however, basolateral Mg2+ transport and its regulation are still poorly understood. Here, by using a candidate screening approach, we identified CNNM2 as a gene involved in renal Mg2+ handling in patients of two unrelated families with unexplained dominant hypomagnesemia. In the kidney, CNNM2 was predominantly found along the basolateral membrane of distal tubular segments involved in Mg2+ reabsorption. The basolateral localization of endogenous and recombinant CNNM2 was confirmed in epithelial kidney cell lines. Electrophysiological analysis showed that CNNM2 mediated Mg2+-sensitive Na+ currents that were significantly diminished in mutant protein and were blocked by increased extracellular Mg2+ concentrations. Our data support the findings of a recent genome-wide association study showing the CNNM2 locus to be associated with serum Mg2+ concentrations. The mutations found in CNNM2, its observed sensitivity to extracellular Mg2+, and its basolateral localization signify a critical role for CNNM2 in epithelial Mg2+ transport.
No comments:
Post a Comment